LZAGY News and Press, Lonza Group AG ADR From 11/17/23

2023-11-17 16:16:14 ET More on Lonza Group AG Lonza: The Day Has Come, And We Lower Our Expectation Lonza Group: Downside Scenario Already Priced In Historical earnings data for Lonza Group AG Dividend scorecard for Lonza Group AG Financial informatio...

2023-10-18 04:43:17 ET Summary Here at the Lab, post Capital Market Day, we are in a show-me-story scenario. Moderna contract termination is a positive short-term catalyst; however, it is an adverse concern over the biotech sector's medium-term growth projections. We still bel...

2023-10-16 10:34:11 ET More on Vaxcyte Strong Financials And Pipeline Position Vaxcyte For Success Seeking Alpha’s Quant Rating on Vaxcyte Historical earnings data for Vaxcyte Financial information for Vaxcyte For further details see: Vaxcy...

2023-10-05 04:55:58 ET Summary Lonza's CEO departure raises questions about business continuity, but we believe the stock price already reflects the worst-case scenario. Lower CAPEX and an ongoing buyback program (with potential M&A flexibility) are a plus given a 'higher for ...

2023-09-24 12:00:08 ET More on COVID vaccine makers Moderna: Covid Curse Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases Novavax: Sell A Covid Bounce Barclays projects over $5B COVID booster sales in fall 2023 Vaccine makers...

2023-09-19 10:56:26 ET More on Moderna Moderna: Buy Before The Fall Covid-19 Wave Moderna slips 8% as Pfizer COVID shot forecast weighs on shares Pfizer sees 24% of eligible Americans getting COVID-19 boosters Pfizer, Moderna And COVID Vaccine Patents: Implic...

2023-09-08 00:03:09 ET Summary The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. ...

2023-07-24 05:26:00 ET Summary Lonza Group lowered its 2023 guidance, reducing its forecast and EBITDA margin outlook. This cut implied an H2 margin deterioration. Despite that, the company's 2024 outlook remains positive, and we see support for the Contract Development and Manufa...

2023-07-21 14:42:35 ET Lonza Group AG press release ( OTCPK:LZAGY ): 1H GAAP EPS of CHF5.54. Revenue of CHF3.07B (+3.0% Y/Y). For further details see: Lonza Group AG GAAP EPS of CHF5.54, revenue of CHF3.07B

2023-07-21 13:10:24 ET Lonza Group AG (LZAGY) Q2 2023 Earnings Conference Call July 21, 2023, 08:00 AM ET Company Participants Pierre-Alain Ruffieux - CEO Philippe Deecke - CFO Conference Call Participants Richard Vosser - JPMorgan James Quigley - Mor...